MISSION

Setting the standard in non-invasive measurement of metabolites in human body fluids to revolutionize patient care and improve quality of life.

TECHNOLOGY

sThesis exploits the potential of a proprietary technology exclusively licensed from the Helmholtz Center Munich. Its broad applicability enables the quantitative measurement of metabolites in human blood at high sensitivity and accuracy while rejecting contaminating signals from other areas of the human body. The company’s current focus is to develop a next-generation sensor for the non-invasive monitoring of in-blood glucose.

TEAM & ADVISORS

Stefan Schorling, CEO & Co-founder ...read more

Vasilis Ntziachristos, Advisor & Co-founder ...read more

Miguel Pleitez, Advisor & Co-founder ...read more

Maximilan Koch, Head of Research ...read more

INITIAL RESULTS

Non-invasive glucose monitoring (NIGM) represents an attractive alternative to finger pricking for blood glucose assessment and management of diabetes.

...read more

TIMELINE

CONTACT

schorling@sthesis-medical.com
+4917661385773
Gautinger Str. 27f
82234 Weßling
Germany